Home LiteratureArticle Details
PMID: 15240517 Published · ppublish English Journal Article

Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.

Fukuoka J, Fujii T, Shih JH, Dracheva T, Meerzaman D, Player A, Hong K, Settnek S, Gupta A, Buetow K, Hewitt S, Travis WD, Jen J

Abstract

We immunohistochemically examined 12 core proteins involved in the chromatin remodeling machinery using a tissue microarray composed of 150 lung adenocarcinoma (AD) and 150 squamous cell carcinoma (SCC) cases. Most of the proteins showed nuclear staining, whereas some also showed cytoplasmic or membranous staining. When the expression patterns of all tested antigens were considered, proteins with nuclear staining clustered into two major groups. Nuclear signals of BRM, Ini-1, retinoblastoma, mSin3A, HDAC1, and HAT1 clustered together, whereas nuclear signals of BRG1, BAF155, HDAC2, BAF170, and RbAP48 formed a second cluster. Additionally, two thirds of the cases on the lung tissue array had follow-up information, and survival analysis was performed for each of the tested proteins. Positive nuclear BRM (N-BRM) staining correlated with a favorable prognosis in SCC and AD patients with a 5 year-survival of 53.5% compared with 32.3% for those whose tumors were negative for N-BRM (P = 0.015). Furthermore, patients whose tumors stained positive for both N-BRM and nuclear BRG1 had a 5 year-survival of 72% compared with 33.6% (P = 0.013) for those whose tumors were positive for either or negative for both markers. In contrast, membranous BRM (M-BRM) staining correlated with a poorer prognosis in AD patients with a 5 year-survival of 16.7% compared with those without M-BRM staining (38.1%; P = 0.016). These results support the notion that BRM and BRG1 participate in two distinct chromosome remodeling complexes that are functionally complementary and that the nuclear presence of BRM, its coexpression with nuclear BRG1, and the altered cellular localization of BRM (M-BRM) are useful markers for non-small cell lung cancer prognosis.

MeSH Terms
Adenocarcinoma/diagnosis,metabolism Adult Aged Aged, 80 and over Antibody Specificity Blotting, Western Carcinoma, Non-Small-Cell Lung/diagnosis,metabolism Carcinoma, Squamous Cell Cell Cycle Proteins/metabolism Cell Nucleus/metabolism Chromatin/metabolism Chromosomes/ultrastructure Cohort Studies Cytoplasm/metabolism DNA Helicases Drosophila Proteins Female Humans Immunohistochemistry Lung/pathology Lung Neoplasms/diagnosis,metabolism Male Middle Aged Nuclear Proteins/metabolism Oligonucleotide Array Sequence Analysis Prognosis Quality Control Retinoblastoma Protein/metabolism Time Factors Trans-Activators/metabolism Transcription Factors/metabolism
Chemicals
Cell Cycle Proteins Chromatin Drosophila Proteins Nuclear Proteins Retinoblastoma Protein Trans-Activators Transcription Factors brm protein, Drosophila SMARCA4 protein, human DNA Helicases
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Fukuoka Junya
Laboratory of Population Genetics, Biometric Research Branch, Center for Bioinformatics, Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA.
Fujii Takeshi
Shih Joanna H
Dracheva Tatiana
Meerzaman Daoud
Player Audrey
Hong Kyeong
Settnek Sharon
Gupta Ajay
Buetow Kenneth
Hewitt Stephen
Travis William D
Jen Jin
Article Info
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Abbr.
Clin Cancer Res
ISSN
1078-0432
Published
2004-07-01
Pages
4314-24
Language
English
Region
United States
NLM ID
9502500
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com